Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in:

Open Access 01-12-2024 | NSCLC | Commentary

Advances in non-small cell lung cancer mechanomedicine: deciphering the signaling networks that govern tumor-TME interactions

Authors: Antonios N. Gargalionis, Kostas A. Papavassiliou, Efthimia K. Basdra, Athanasios G. Papavassiliou

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

Cells from the tumor microenvironment (TME) interact with tumor cells in non-small cell lung cancer (NSCLC) to form a reciprocal crosstalk which influences tumor growth, proliferation, metastasis and multidrug response. This crosstalk is modulated by TME mechanical inputs, which elicit the processes of mechanosensing and mechanotransduction. Recent advances in unveiling these signaling networks establish the interdisciplinary field of mechanomedicine to exploit emerging diagnostic, predictive and therapeutic tools for more effective NSCLC treatments.
Literature
1.
Zhou H, Wang M, Zhang Y, Su Q, Xie Z, Chen X, Yan R, Li P, Li T, Qin X, et al. Functions and clinical significance of mechanical tumor microenvironment: cancer cell sensing, mechanobiology and metastasis. Cancer Commun (Lond). 2022;42:374–400.CrossRefPubMed
2.
3.
Kalli M, Poskus MD, Stylianopoulos T, Zervantonakis IK. Beyond matrix stiffness: targeting force-induced cancer drug resistance. Trends Cancer. 2023;9:937–54.CrossRefPubMedPubMedCentral
4.
Mai Z, Lin Y, Lin P, Zhao X, Cui L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15:307.CrossRefPubMedPubMedCentral
5.
Wang Y, Zhang T, Guo L, Ren T, Yang Y. Stromal extracellular matrix is a microenvironmental cue promoting resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. Int J Biochem Cell Biol. 2019;106:96–106.CrossRefPubMed
6.
Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9:4692.CrossRefPubMedPubMedCentral
7.
Wu J, Zhang Q, Yang Z, Xu Y, Liu X, Wang X, Peng J, Xiao J, Wang Y, Shang Z, et al. CD248-expressing cancer-associated fibroblasts induce non-small cell lung cancer metastasis via Hippo pathway-mediated extracellular matrix stiffness. J Cell Mol Med. 2024;28: e70025.CrossRefPubMedPubMedCentral
8.
Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, et al. Focal Irradiation and Systemic TGFbeta Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018;24:2493–504.CrossRefPubMedPubMedCentral
9.
Park Y, Lee D, Lee JE, Park HS, Jung SS, Park D, Kang DH, Lee SI, Woo SD, Chung C. The Matrix Stiffness Coordinates the Cell Proliferation and PD-L1 Expression via YAP in Lung Adenocarcinoma. Cancers (Basel). 2024;16:598.CrossRefPubMedPubMedCentral
10.
Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH, Lim DS, Choi W, Lee DH, Yoo G, et al. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophys Res Commun. 2017;491:493–9.CrossRefPubMed
11.
Yuan Y, Zhong W, Ma G, Zhang B, Tian H. Yes-associated protein regulates the growth of human non-small cell lung cancer in response to matrix stiffness. Mol Med Rep. 2015;11:4267–72.CrossRefPubMed
12.
Wu P, Gao W, Su M, Nice EC, Zhang W, Lin J, Xie N. Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Front Cell Dev Biol. 2021;9: 641469.CrossRefPubMedPubMedCentral
13.
Liang M, Sun Z, Chen X, Wang L, Wang H, Qin L, Zhao W, Geng B. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells. J Exp Clin Cancer Res. 2023;42:275.CrossRefPubMedPubMedCentral
14.
Cohen M, Giladi A, Barboy O, Hamon P, Li B, Zada M, Gurevich-Shapiro A, Beccaria CG, David E, Maier BB, et al. The interaction of CD4(+) helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nat Cancer. 2022;3:303–17.CrossRefPubMed
15.
Yu KX, Yuan WJ, Wang HZ, Li YX. Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion. Cancer Immunol Immunother. 2024;73:115.CrossRefPubMedPubMedCentral
16.
Ma C, Luo H, Cao J, Zheng X, Zhang J, Zhang Y, Fu Z. Identification of a Novel Tumor Microenvironment-Associated Eight-Gene Signature for Prognosis Prediction in Lung Adenocarcinoma. Front Mol Biosci. 2020;7: 571641.CrossRefPubMedPubMedCentral
17.
Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015;47:250–6.CrossRefPubMedPubMedCentral
18.
Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim J. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J. 2016;35:462–78.CrossRefPubMed
19.
Aykut B, Chen R, Kim JI, Wu D, Shadaloey SAA, Abengozar R, Preiss P, Saxena A, Pushalkar S, Leinwand J, et al. Targeting Piezo1 unleashes innate immunity against cancer and infectious disease. Sci Immunol. 2020;5:eabb5168.CrossRefPubMed
20.
Lu M, Xu Z, Xu F, Yin C, Guo H, Cheng B. Mechanical network motifs as targets for mechanomedicine. Drug Discov Today. 2024;29: 104145.CrossRefPubMed
21.
Jiang Y, Xie WJ, Chen RW, You WW, Ye WL, Chen H, Chen WX, Xu JP. The Hippo Signaling Core Components YAP and TAZ as New Prognostic Factors in Lung Cancer. Front Surg. 2022;9: 813123.CrossRefPubMedPubMedCentral
22.
Cisowski J, O’Callaghan K, Kuliopulos A, Yang J, Nguyen N, Deng Q, Yang E, Fogel M, Tressel S, Foley C, et al. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol. 2011;179:513–23.CrossRefPubMedPubMedCentral
23.
Gong F, Yang Y, Wen L, Wang C, Li J, Dai J. An Overview of the Role of Mechanical Stretching in the Progression of Lung Cancer. Front Cell Dev Biol. 2021;9: 781828.CrossRefPubMedPubMedCentral
24.
Wang WH, Hsu CL, Huang HC, Juan HF. Quantitative Phosphoproteomics Reveals Cell Alignment and Mitochondrial Length Change under Cyclic Stretching in Lung Cells. Int J Mol Sci. 2020;21:4074.CrossRefPubMedPubMedCentral
25.
Hendricks P, Diaz FJ, Schmitt S, Sitta Sittampalam G, Nirmalanandhan VS. Effects of respiratory mechanical forces on the pharmacological response of lung cancer cells to chemotherapeutic agents. Fundam Clin Pharmacol. 2012;26:632–43.CrossRefPubMed
26.
Shen S, Li Y, Xiao Y, Zhao Z, Zhang C, Wang J, Li H, Liu F, He N, Yuan Y, et al. Folate-conjugated nanobubbles selectively target and kill cancer cells via ultrasound-triggered intracellular explosion. Biomaterials. 2018;181:293–306.CrossRefPubMed
27.
Tijore A, Yao M, Wang YH, Hariharan A, Nematbakhsh Y, Lee Doss B, Lim CT, Sheetz M. Selective killing of transformed cells by mechanical stretch. Biomaterials. 2021;275: 120866.CrossRefPubMed
28.
29.
30.
31.
Wei R, Liu S, Zhang S, Min L, Zhu S. Cellular and Extracellular Components in Tumor Microenvironment and Their Application in Early Diagnosis of Cancers. Anal Cell Pathol (Amst). 2020;2020:6283796.PubMed
32.
Wang S, Rong R, Yang DM, Fujimoto J, Yan S, Cai L, Yang L, Luo D, Behrens C, Parra ER, et al. Computational Staining of Pathology Images to Study the Tumor Microenvironment in Lung Cancer. Cancer Res. 2020;80:2056–66.CrossRefPubMedPubMedCentral
Metadata
Title
Advances in non-small cell lung cancer mechanomedicine: deciphering the signaling networks that govern tumor-TME interactions
Authors
Antonios N. Gargalionis
Kostas A. Papavassiliou
Efthimia K. Basdra
Athanasios G. Papavassiliou
Publication date
01-12-2024
Publisher
BioMed Central
Keywords
NSCLC
NSCLC
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-024-03242-1

Other articles of this Issue 1/2024

Enhancer looping protein LDB1 modulates MYB expression in T-ALL cell lines in vitro by cooperating with master transcription factors

A complex of cadherin 17 with desmocollin 1 and p120-catenin regulates colorectal cancer migration and invasion according to the cell phenotype

Hepatocyte-derived Igκ promotes HCC progression by stabilizing electron transfer flavoprotein subunit α to facilitate fatty acid β-oxidation

PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility

ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages

  • Open Access
  • NSCLC
  • Research

LncRNA AL139294.1 can be transported by extracellular vesicles to promote the oncogenic behaviour of recipient cells through activation of the Wnt and NF-κB2 pathways in non-small-cell lung cancer

  • Open Access
  • NSCLC
  • Research

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits